Gotham, Mercachem create molecule library for RNA-modifying drug discovery

By Vassia Barba

- Last updated on GMT

(Image: Getty/123dartist)
(Image: Getty/123dartist)

Related tags Gotham Therapeutics Mercachem Preclinical contract research preclinical preclinical development Preclinical services

A collaboration between Mercachem and Gotham leads to the generation of a molecule library, expected to enable new discovery opportunities in the epitranscriptomic targets space.

Gotham Therapeutics, a biotechnology development company focused on RNA-modifying proteins, announced the creation of the molecule library, as a result of a collaboration with Mercachem, a contract research organization (CRO) offering medicinal chemistry and early process research services.

The library enables researchers to identify small-molecule master keys able to unlock novel targets and address the specific pharmacophoric features that this target family shares, according to the CSO of Gotham, Gerhard Müller.

The partners have produced more than 2,000 analogs and over 80 distinct chemotypes with increased affinity, comprising several structures for binding to epitranscriptomic targets, whilst demonstrating and utilizing cross-target synergies.

In addition, the library will enable the companies to provide hit generation and expand its hit-to-lead in the epitranscriptomic target space to accelerate Gotham’s current lead program.

“The library will be repeatedly explored as we continue our collaboration with Mercachem in all future pipeline projects along the hit-to-lead candidate trajectory,”​ Müller said in a statement.

Frank Leemhuis, managing director of Mercachem, commented on his side: “We look forward to seeing the progress Gotham aims to make in the epitranscriptomic space with the assets and knowhow gleaned as part of our collaboration.”

Related news

Show more

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Content provided by Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more